EUCTR2009-012376-27-IT进行中（未招募）1 期
EFFECTS OF LONG-ACTING SOMATOSTATIN ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE/SEVERE RENAL INSUFFICIENCY(ALADIN II STUDY) - ALADIN II
IST. DI RICERCHE FARMACOLOG. M. NEGRI0 个研究点目标入组 80 人开始时间: 2009年11月30日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age > 18 years Clinical and ultrasound diagnosis of ADPKD Estimated GFR between 40-15 ml/min/1.73m2 (by the MDRD 4 variable equation) Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Diabetes Mellitus Other primary or secondary renal diseases. Proteinuria excretion rate >1g/24 hours or abnormal urinalysis suggestive of concomitant glomerular disease Urinary tract lithiasis or obstruction Current urinary tract infection Biliary tract lithiasis Active cancer Psychiatric disorders or any condition that might prevent full comprehension of the purposes and risks of the study Pregnancy, lactation or child bearing potential and ineffective contraception (estrogen therapy in post menopausal women should not be stopped)
研究者
相似试验
进行中（未招募）
1 期
Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant polycystic disease a long-term three year follow-up study - ALADIAutosomal Dominant Polycystic Kidney Disease ADPKDMedDRA version: 6.1 Level: SOC Classification code 10038359EUCTR2005-005552-41-ITIST. DI RICERCHE FARMACOLOG. M. NEGRI66
招募中
不适用
The effect of somatostatin for treatment of post hepatectomy liver failure (PHLF)Diseases of the digestive systemKCT0001977Korea University Anam Hospital20
进行中（未招募）
1 期
The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding.EUCTR2018-004179-11-NLRadboudumc38
尚未招募
不适用
Onderzoek naar de effectiviteit van octreotide in hereditary hemorrhagic telangiectasia patiënten metdaarbij gastrointestinale bloedingen.NL-OMON25382Radboudumc38
进行中（未招募）
1 期
The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber disease) patients who suffer fromgastrointestinal bleeding.EUCTR2018-004179-11-DERadboudumc38